Physician profile
Darrell Leroy Widmer
NPI 1629048079
$1,486.13
in general payments reported to CMS, 2019-2025
19 companies · $200 in 2025
The $200 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $769 · 2020: $34.63 · 2021: $11.00 · 2022: $122 · 2023: $99.31 · 2024: $250 · 2025: $200.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $549.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $549.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $371.91 | 2019-2025 | Breztri |
| Novo Nordisk INC | $172.18 | 2019-2025 | Ozempic, Rybelsus |
| Pfizer INC. | $143.60 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $137.47 | 2019-2023 | |
| Glaxosmithkline, LLC. | $102.53 | 2019-2025 | Shingrix, Rotarix, Bexsero |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $84.96 | 2019-2024 | Xifaxan |
| Exact Sciences Corporation | $71.37 | 2024-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Dynavax Technologies Corporation | $70.34 | 2021-2024 | Heplisav-B |
| Amarin Pharma, INC. | $66.08 | 2019-2022 | |
| Lilly USA, LLC | $56.96 | 2019-2025 | Mounjaro, Zepbound |
| Novartis Pharmaceuticals Corporation | $53.09 | 2019-2023 | |
| Amgen INC. | $43.93 | 2023-2025 | Krystexxa, Otezla, Repatha |
| Abbvie INC. | $29.35 | 2024 | |
| Astellas Pharma US INC | $20.51 | 2023 | Veozah |
| Strongbridge US INC. | $15.70 | 2019 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $11.64 | 2019 | |
| Janssen Pharmaceuticals, INC | $11.60 | 2019 | |
| Allergan, INC. | $11.54 | 2020 | |
| E.R. Squibb & Sons, L.L.C. | $11.37 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Darrell Widmer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.